These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1180 related articles for article (PubMed ID: 19179406)

  • 1. The prognostic value of repeated measurement of N-terminal pro-B-type natriuretic peptide in patients with chronic heart failure due to left ventricular systolic dysfunction.
    Kubánek M; Goode KM; Lánská V; Clark AL; Cleland JG
    Eur J Heart Fail; 2009 Apr; 11(4):367-77. PubMed ID: 19179406
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison of midregional pro-atrial and B-type natriuretic peptides in chronic heart failure: influencing factors, detection of left ventricular systolic dysfunction, and prediction of death.
    Moertl D; Berger R; Struck J; Gleiss A; Hammer A; Morgenthaler NG; Bergmann A; Huelsmann M; Pacher R
    J Am Coll Cardiol; 2009 May; 53(19):1783-90. PubMed ID: 19422985
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Long-term results of intensified, N-terminal-pro-B-type natriuretic peptide-guided versus symptom-guided treatment in elderly patients with heart failure: five-year follow-up from TIME-CHF.
    Sanders-van Wijk S; Maeder MT; Nietlispach F; Rickli H; Estlinbaum W; Erne P; Rickenbacher P; Peter M; Pfisterer MP; Brunner-La Rocca HP;
    Circ Heart Fail; 2014 Jan; 7(1):131-9. PubMed ID: 24352403
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Diagnostic value of N-terminal pro-B-type natriuretic peptide (NT-proBNP) for left ventricular dysfunction in patients with chronic kidney disease stage 5 on haemodialysis.
    David S; Kümpers P; Seidler V; Biertz F; Haller H; Fliser D
    Nephrol Dial Transplant; 2008 Apr; 23(4):1370-7. PubMed ID: 18089624
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cutoff values of NT-proBNP for the prediction of low functional capacity, decreased ejection fraction and cardiovascular events in patients with heart failure.
    Koç M; Bozkurt A; Yildiray-Sahin D; Unal I; Acartürk E
    Cardiol J; 2009; 16(1):43-9. PubMed ID: 19130415
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of midregional pro-atrial natriuretic peptide with N-terminal pro-B-type natriuretic peptide in predicting survival in patients with chronic heart failure.
    von Haehling S; Jankowska EA; Morgenthaler NG; Vassanelli C; Zanolla L; Rozentryt P; Filippatos GS; Doehner W; Koehler F; Papassotiriou J; Kremastinos DT; Banasiak W; Struck J; Ponikowski P; Bergmann A; Anker SD
    J Am Coll Cardiol; 2007 Nov; 50(20):1973-80. PubMed ID: 17996563
    [TBL] [Abstract][Full Text] [Related]  

  • 7. N-terminal pro-B-type natriuretic peptide as a diagnostic test for ventricular dysfunction in patients with coronary disease: data from the heart and soul study.
    Corteville DC; Bibbins-Domingo K; Wu AH; Ali S; Schiller NB; Whooley MA
    Arch Intern Med; 2007 Mar; 167(5):483-9. PubMed ID: 17353496
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prognostic value of NT-proBNP at rest and peak exercise in patients with impaired left ventricular function.
    Kallistratos MS; Pavlidis AN; Chamodraka ES; Varounis C; Dritsas A; Laoutaris ID; Manolis AJ; Cokkinos DV
    Angiology; 2012 Oct; 63(7):516-21. PubMed ID: 22156406
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Changes of plasma norepinephrine and serum N-terminal pro-brain natriuretic peptide after exercise training predict survival in patients with heart failure.
    Rengo G; Pagano G; Parisi V; Femminella GD; de Lucia C; Liccardo D; Cannavo A; Zincarelli C; Komici K; Paolillo S; Fusco F; Koch WJ; Perrone Filardi P; Ferrara N; Leosco D
    Int J Cardiol; 2014 Feb; 171(3):384-9. PubMed ID: 24388546
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prognostic usefulness of the change in N-terminal pro B-type natriuretic peptide levels to predict mortality in a single community cohort aged ≥ 70 years.
    Eggers KM; Venge P; Lind L
    Am J Cardiol; 2013 Jan; 111(1):131-6. PubMed ID: 23040598
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prognostic value of N-terminal pro-type-B natriuretic peptide and Doppler left ventricular diastolic variables in patients with chronic systolic heart failure stabilized by therapy.
    Dini FL; Conti U; Fontanive P; Andreini D; Panicucci E; De Tommasi SM
    Am J Cardiol; 2008 Aug; 102(4):463-8. PubMed ID: 18678307
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Long-term prognostic value and serial changes of plasma N-terminal prohormone B-type natriuretic peptide in patients undergoing transcatheter aortic valve implantation.
    Ribeiro HB; Urena M; Le Ven F; Nombela-Franco L; Allende R; Clavel MA; Dahou A; Côté M; Laflamme J; Laflamme L; DeLarochellière H; DeLarochellière R; Doyle D; Dumont E; Bergeron S; Pibarot P; Rodés-Cabau J
    Am J Cardiol; 2014 Mar; 113(5):851-9. PubMed ID: 24528616
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prognostic utility of the Seattle Heart Failure Score and amino terminal pro B-type natriuretic peptide in varying stages of systolic heart failure.
    Adlbrecht C; Hülsmann M; Neuhold S; Strunk G; Pacher R
    J Heart Lung Transplant; 2013 May; 32(5):533-8. PubMed ID: 23453573
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pro-brain natriuretic peptide plasma levels, left ventricular dimensions and ejection fraction in acute dyspnoea.
    Shaikh K; Hanif B; Siddique AA; Shaikh MY; Khan MN
    J Coll Physicians Surg Pak; 2012 Dec; 22(12):751-5. PubMed ID: 23217478
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Characterization and prediction of natriuretic peptide "nonresponse" during heart failure management: results from the ProBNP Outpatient Tailored Chronic Heart Failure (PROTECT) and the NT-proBNP-Assisted Treatment to Lessen Serial Cardiac Readmissions and Death (BATTLESCARRED) study.
    Gaggin HK; Truong QA; Rehman SU; Mohammed AA; Bhardwaj A; Parks KA; Sullivan DA; Chen-Tournoux A; Moore SA; Richards AM; Troughton RW; Lainchbury JG; Weiner RB; Baggish AL; Semigran MJ; Januzzi JL
    Congest Heart Fail; 2013; 19(3):135-42. PubMed ID: 23279139
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of ivabradine therapy on heart failure biomarkers.
    Ordu S; Yildiz BS; Alihanoglu YI; Ozsoy A; Tosun M; Evrengul H; Kaftan HA; Ozhan H
    Cardiol J; 2015; 22(5):501-9. PubMed ID: 25733317
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pro-A-type natriuretic peptide, proadrenomedullin, and N-terminal pro-B-type natriuretic peptide used in a multimarker strategy in primary health care in risk assessment of patients with symptoms of heart failure.
    Alehagen U; Dahlström U; Rehfeld JF; Goetze JP
    J Card Fail; 2013 Jan; 19(1):31-9. PubMed ID: 23273592
    [TBL] [Abstract][Full Text] [Related]  

  • 18. N-terminal fraction of pro-B-type natriuretic peptide versus clinical risk scores for prognostic stratification in chronic systolic heart failure.
    Arzilli C; Aimo A; Vergaro G; Ripoli A; Senni M; Emdin M; Passino C
    Eur J Prev Cardiol; 2018 May; 25(8):889-895. PubMed ID: 29569494
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Atrial fibrillation and amino-terminal pro-brain natriuretic peptide as independent predictors of prognosis in systolic heart failure.
    Dini FL; Gabutti A; Passino C; Fontanive P; Emdin M; De Tommasi SM
    Int J Cardiol; 2010 Apr; 140(3):344-50. PubMed ID: 19128846
    [TBL] [Abstract][Full Text] [Related]  

  • 20. N-terminal pro-B-type natriuretic peptide is a specific predictor of appropriate device therapies in patients with primary prevention implantable cardioverter-defibrillators.
    Sroubek J; Matos J; Locke A; Kaplinskiy V; Levine YC; Shen C; Buxton AE
    Heart Rhythm; 2021 Jan; 18(1):71-78. PubMed ID: 32866691
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 59.